CDK4/6 Inhibitors for Metastatic Breast Cancer CDK4 and CDK6 are enzymes important in cell division. CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells. CDK4/6 inhibitors are used in combination with hormone therapy to treat some hormone receptor-positive breast cancers. The CDK4/6 inhibitors FDA-approved for metastatic breast cancer treatment are: Drug name […]| Susan G. Komen®
Hormone receptor status and HER2 status are the main factors in planning breast cancer treatment.| Susan G. Komen®
Learn how hormone therapies can slow or stop the growth of hormone receptor-positive breast cancer tumors by preventing the cancer cells from getting the hormones they need to grow.| Susan G. Komen®
Metastatic breast cancer (stage IV) is the most advanced stage of breast cancer. Learn about treatments for metastatic breast cancer.| Susan G. Komen®
In this episode of Breast Cancer Breakthroughs, we speak with Komen grantees Dr. Tarah Ballinger, medical oncologist at Indiana University School of Medicine, and Dr. Pedram Razavi, medical oncologist at Memorial Sloan Kettering Cancer Center, about the biggest highlights from the 2024 ASCO Annual Meeting and what they could mean for patients.| Susan G. Komen®
